Has Andrew Pachner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,476 in general payments to Andrew Pachner, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Pachner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Pachner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Pachner, MD

Neurology · Lebanon, NHNPI 1720111867

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,552 of the $31,476 with a category attached, or 71.6%. 3 manufacturers reported payments, led by EMD Serono, Inc. at 53.3% of the total. Among neurology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,476in general payments, 2019–2025

Across 33 payments — averaging $953.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

EMD Serono, Inc.$17K
Biogen$9K
AstraZeneca$5K

$178,514in research payments, 2019–2025

Across 11 payments — averaging $16,229 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$120K
Biogen$40K
EMD Serono, Inc.$18K

What the payments were for

Consulting fees$22,55272%
Speaking & faculty fees$3,82512%
Travel & lodging$4,20313%
Food & beverage$8963%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
EMD Serono, Inc.	16	$16,768
Biogen	8	$9,252
AstraZeneca	9	$5,457

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PLEGRIDY$7,424
SOLIRIS$5,358
AVONEX$4,274
Mavenclad$655

How this compares

$31,476 in reported general payments places this provider in the 95th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$8,869

Medicare patients

Services billed

117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TecfideraDimethyl Fumarate	25	$223,643
Rebif RebidoseInterferon Beta-1a/Albumin	12	$124,675
GilenyaFingolimod Hcl	11	$103,427
FingolimodFingolimod Hcl	63	$31,787
Teriflunomide	24	$24,389
Dalfampridine ErDalfampridine	16	$5,888
Dimethyl Fumarate	14	$2,244
Tizanidine Hcl	14	$771
Gabapentin	21	$541
Baclofen	30	$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
BiogenTecfidera	$9,252	$223,64325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 neurology providers in New Hampshire.

Other neurology in Lebanon

Oliver PhillipsLebanon$50K
Jeffrey CohenLebanon$18K
Jianhui ZhangLebanon$12K
Francis BenzLebanon$8K
Thomas WardLebanon$5K
Diana LiLebanon$4K
Steven CherryLebanon$2K
Timothy LukovitsLebanon$2K
Nicole OdomLebanon$2K
George CullerLebanon$1K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →